Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1942
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Dextrose (Injection, Solution)
|
| dailymed-instance:dosage |
As directed by a
physician. Dosage is dependent upon the age, weight and clinical
condition of the patient as well as laboratory determinations. Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container
permit. Do not administer
unless solution is clear and seal is intact. All injections in
AVIVA plastic containers are intended for intravenous administration
using sterile equipment. Additives may be
incompatible. Complete information is not available. Those additives
known to be incompatible should not be used. Consult with pharmacist, if
available. If, in the informed judgment of the physician, it is deemed
advisable to introduce additives, use aseptic technique. Mix thoroughly
when additives have been introduced. Do not store solutions containing
additives.
|
| dailymed-instance:descripti... |
Dextrose Injection,
USP is a sterile, nonpyrogenic solution for fluid replenishment and
caloric supply in single dose containers for intravenous administration.
It contains no antimicrobial agents. Composition, osmolarity, pH, and
caloric content are shown in Table 1 The flexible
container is made with non-latex plastic materials specially designed
for a wide range of parenteral drugs including those requiring delivery
in containers made of polyolefins or polypropylene. For example, the
AVIVA container system is compatible with and appropriate for use in the
admixture and administration of paclitaxel. In addition, the AVIVA
container system is compatible with and appropriate for use in the
admixture and administration of all drugs deemed compatible with
existing polyvinyl chloride container systems. The solution contact
materials do not contain PVC, DEHP, or other plasticizers. The suitability of
the container materials has been established through biological
evaluations, which have shown the container passes Class VI U.S.
Pharmacopeia (USP) testing for plastic containers. These tests confirm
the biological safety of the container system. The flexible
container is a closed system, and air is prefilled in the container to
facilitate drainage. The container does not require entry of external
air during administration. The container has
two ports: one is the administration outlet port for attachment of an
intravenous administration set and the other port has a medication site
for addition of supplemental medication (See Directions for
Use). The primary function of the overwrap is to protect the
container from the physical environment.
|
| dailymed-instance:clinicalP... |
Dextrose Injection,
USP has value as a source of water and calories. It is capable of
inducing diuresis depending on the clinical condition of the
patient.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Solutions
containing dextrose may be contraindicated in patients with known
allergy to corn or corn products.
|
| dailymed-instance:supply |
Dextrose Injection,
USP in AVIVA plastic container is available as follows: Exposure of
pharmaceutical products to heat should be minimized. Avoid excessive
heat. It is recommended the product be stored at room temperature
(25��C/ 77��F); brief exposure up to 40��C/
104��F does not adversely affect the product.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
General: Do not
connect flexible plastic containers of intravenous solutions in
series connections. Such use could result in air embolism due to
residual air being drawn from one container before
administration of the fluid from a secondary container is
completed. Pressurizing intravenous solutions contained in flexible
plastic containers to increase flow rates can result in air
embolism if the residual air in the container is not fully
evacuated prior to administration. Use of a
vented intravenous administration set with the vent in the open
position could result in air embolism. Vented intravenous
administration sets with the vent in the open position should
not be used with flexible plastic containers. Dextrose
Injection, USP should be used with caution in patients with
overt or subclinical diabetes mellitus.<br/>Laboratory Tests: Clinical
evaluation and periodic laboratory determinations are necessary
to monitor changes in fluid balance, electrolyte concentrations,
and acid base balance during prolonged parenteral therapy or
whenever the condition of the patient warrants such
evaluation.<br/>Drug Interactions: Studies
have not been conducted to evaluate additional drug/drug or
drug/food interactions with Dextrose Injection, USP.<br/>Carcinogenesis,
Mutagenesis, Impairment of Fertility: Studies
with Dextrose Injection, USP have not been performed to evaluate
carcinogenic potential, mutagenic potential, or effects on
fertility.<br/>Pregnancy:<br/>Teratogenic
Effects:<br/>Labor and Delivery: Studies
have not been conducted to evaluate the effects of Dextrose
Injection, USP on labor and delivery. Caution should be
exercised when administering this drug during labor and
delivery.<br/>Nursing Mothers: It is not
known whether this drug is excreted in human milk. Because many
drugs are excreted in human milk, caution should be exercised
when Dextrose Injection, USP is administered to a nursing
mother.<br/>Pediatric Use: Dextrose
Injection, USP is safe and effective for the stated indications
in pediatric patients (see INDICATIONS
AND USAGE). As reported in the literature, the
dosage selection and constant infusion rate of intravenous
dextrose must be selected with caution in pediatric patients,
particularly neonates and low birth weight infants, because of
the increased risk of hyperglycemia/ hypoglycemia. Frequent
monitoring of serum glucose concentrations is required when
dextrose is prescribed to pediatric patients, particularly
neonates and low birth weight infants.<br/>Geriatric Use: Clinical
studies of Dextrose Injection, USP did not include sufficient
numbers of subjects aged 65 and over to determine whether they
respond differently from younger subjects. Other reported
clinical experience has not identified differences in responses
between the elderly and younger patients. In general, dose
selection for an elderly patient should be cautious, usually
starting at the low end of the dosing range, reflecting the
greater frequency of decreased hepatic, renal, or cardiac
function, and of concomitant disease or drug therapy. This drug
is known to be substantially excreted by the kidney, and the
risk of toxic reactions to this drug may be greater in patients
with impaired renal function. Because elderly patients are more
likely to have decreased renal function, care should be taken in
dose selection, and it may be useful to monitor renal
function.
|
| dailymed-instance:genericMe... |
Dextrose monohydrate
|
| dailymed-instance:fullName |
Dextrose (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Reactions which may
occur because of the injection or the technique of administration
include febrile response, infection at the site of injection, venous
thrombosis or phlebitis extending from the site of injection,
extravasation and hypervolemia. If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures and save the remainder
of the fluid for examination if deemed necessary.
|
| dailymed-instance:warning |
Dextrose Injection,
USP should not be administered simultaneously with blood through the
same administration set because of the possibility of
pseudoagglutination or hemolysis. The intravenous
administration of these solutions can cause fluid and/or solute
overloading resulting in dilution of serum electrolyte concentrations,
overhydration, congested states, or pulmonary edema. The risk of
dilutive states is inversely proportional to the electrolyte
concentrations of the injections. The risk of solute overload causing
congested states with peripheral and pulmonary edema is directly
proportional to the electrolyte concentrations of the injections. Excessive
administration of dextrose injections may result in significant
hypokalemia. In very low birth
weight infants, excessive or rapid administration of dextrose injection
may result in increased serum osmolality and possible intracerebral
hemorrhage.
|
| dailymed-instance:indicatio... |
Dextrose Injection,
USP is indicated as a source of water and calories.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Dextrose
|